Disclaimer:
For research use only. Not for human consumption. Intended for laboratory-based studies by qualified professionals. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
 
Overview:
Retatrutide is a cutting-edge triple agonist peptide targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It represents the next evolution in incretin-based research, combining the metabolic benefits of multiple hormonal pathways to explore enhanced weight reduction, glucose regulation, and energy expenditure in preclinical and clinical models.
Mechanism of Action:
Retatrutide simultaneously activates three incretin and glucagon receptors:
GLP-1 receptor activation promotes insulin secretion, delays gastric emptying, and enhances satiety.
GIP receptor activation improves insulin response and lipid metabolism.
Glucagon receptor activation increases energy expenditure and fat oxidation.
This multi-receptor synergy creates a comprehensive metabolic response, supporting research into advanced weight management, glucose control, and energy regulation.
Research Highlights:
Demonstrated superior body weight and fat mass reduction compared to single or dual incretin analogs.
Shown to enhance insulin sensitivity and metabolic efficiency in preclinical studies.
Studied for potential applications in obesity, diabetes, and cardiometabolic disease models.
Represents a next-generation approach to incretin-based metabolic therapy research.
Specifications:
Form: Lyophilized powder (research-grade)
Purity: ≥98% (HPLC-tested)
Storage: Store refrigerated (2–8 °C), protected from moisture and light.